INTRODUCTION {#s1}
============

Glioma is a general term used to describe any tumor that arises from the supportive (gluey) tissue of the brain. This tissue, called glia, helps to keep the neurons in place and functioning well. It is the most common and aggressive primary brain tumors, occurring most commonly in adults and accounting for 40--50% of all brain tumors \[[@R1]\]. According to the 2007 World Health Organization (WHO) classification, gliomas are subclassified into four grades based on degree of aggressiveness: grade I (pilocytic astrocytomas), grade II (diffuse infiltrating low-grade gliomas), grade III (anaplastic gliomas), and grade IV (glioblastomas multiforme) \[[@R2]\]. Low-grade gliomas (grade I--II) are well differentiated, and generally have better prognoses than high-grade gliomas (grade III--IV) \[[@R2], [@R3]\]. Despite total or near-total tumor resection, and advancements in chemo-radiotherapy, patient outcomes remain dismal. Median survival times for patients with grade III and IV gliomas are only 39 and 30 weeks, respectively \[[@R4]\].

Several clinical factors, such as surgical method, radiotherapy, chemotherapy, patient age and gender, and tumor grade, size, range and location, can affect glioma patient prognosis. Most gliomas result from the combined action of environmental factors and inherited genetic variations \[[@R5]\]. Haque, *et al.* \[[@R6]\] suggested that glioblastoma arises from genetic and epigenetic alterations in normal astroglial cells, implying that genetic factors are primarily responsible for gliomagenesis.

Interleukin-10 (IL-10), an important anti-inflammatory cytokine, is secreted by various immune cells. IL-10 has pleiotropic effects on immunoregulation and inflammation, and can promote carcinogenesis \[[@R7]\]. Huettner, *et al.* \[[@R8]\] suggested that IL-10 promotes glioma progression by enhancing tumor cell invasion and providing an immunosuppressive environment. Additionally, *IL-10* polymorphisms are associated with glioblastoma \[[@R9]\].

PRKDC, also known as human X-ray repair cross-complementing group 7 (*XRCC7*), is located on chromosome 8q11. Several studies have associated *PRKDC* with poor prognosis in numerous tumor types, such as esophageal cancer \[[@R10]\], B-cell chronic lymphocytic leukemias \[[@R11]\], and colorectal cancer \[[@R12]\]. *PRKDC* gene polymorphisms are also correlated with glioma risk \[[@R13], [@R14]\].

Although previous association studies linked *IL-10* and *PRKDC* genetic polymorphisms with glioma risk, few focused on the effects of these alterations on glioma patient prognosis. In the present study, we selected one single nucleotide polymorphism (SNP) in *IL-10* \[[@R9]\] and one in *PRKDC* \[[@R14]\], each of which was reportedly associated with glioma risk. We evaluated the associations between these two SNPs and low- and high-grade glioma patient prognosis in a Chinese population.

RESULTS {#s2}
=======

Patient clinical data {#s2_1}
---------------------

A total of 481 glioma patients were analyzed in this study, including 300 astrocytomas, 70 oligodendrocytomas, 43 glioblastomas, 31 ependymomas, 14 oligodendrogliomas, and 23 other types of gliomas. Detailed clinical data for glioma patients are summarized in Table [1](#T1){ref-type="table"}. Patients included 264 (54.9%) men and 217 (45.1%) women, with 208 patients \< 40 years of age and 273 ≥ 40 years of age. A total of 35 (7.3%) patients were classified as WHO grade I, 259 (53.8%) as WHO grade II, 124 (25.8%) as WHO grade III and 63 (13.1%) as WHO grade IV. 328 (68.2%) patients received gross-total tumor surgical resections and 153 (31.3%) received near-total or sub-total resections. Gamma knife radiotherapy was administered to 315 (65.5%) patients and conformal radiation therapy was administered to 122 (25.4%). Finally, 198 (41.1%) patients received chemotherapy. 438 (91.1%) patients had died at the last follow-up and 453 (94.2%) progressed during follow-up.

###### Characteristics of glioma patients

  Variable              Classification   Glioma   I-II   III-IV                
  --------------------- ---------------- -------- ------ -------- ------ ----- ------
  Gender                Male             264      54.9   157      53.4   107   57.2
                        Female           217      45.1   137      46.6   80    42.8
  Age(years)            \< 40            208      43.2   144      49.0   64    34.2
                        ≥ 40             273      56.8   150      51.0   123   65.8
  WHO grade             WHO I            35       7.3    35       11.9         
                        WHO II           259      53.8   259      88.1         
                        WHO III          124      25.8                   124   66.3
                        WHO IV           63       13.1                   63    33.7
  Extent of resection   GTR              328      68.2   197      67.0   131   70.1
                        STR or NTR       153      31.8   97       33.0   56    29.9
  Radiotherapy          GK               315      65.5   197      67.0   118   63.1
                        CRT              122      25.4   73       24.8   49    26.2
                        No               44       9.1    24       8.2    20    10.7
  Chemotherapy          Platinum         101      21.0   63       21.4   38    20.3
                        Nimustine        60       12.5   35       11.9   25    13.4
                        Temozolomide     37       7.7    26       8.8    11    5.9
                        No               283      58.8   170      57.8   113   60.4
  Survival condition    Survival         26       5.4    17       5.8    9     4.8
                        Lost             17       3.5    14       4.8    3     1.6
                        Death            438      91.1   263      89.5   175   93.6
  Progress              Yes              453      94.2   275      93.5   178   95.2
                        No               24       5.0    17       5.8    7     3.7
                        Missing system   4        0.8    2        0.7    2     1.1

WHO: World Health Organization; GTR: Gross-total resection; NTR: Near-total resection; STR: Sub-total resection; GK: Gamma knife; CRT: Conformal radiation therapy.

Univariate analysis {#s2_2}
-------------------

In a univariate analysis of clinical factors, including patient gender and age, extent of tumor resection, and radiotherapy and chemotherapy regimen, we found that the median overall survival (OS) of WHO grade I--II glioma patients (12 months; 3-year survival rate = 9.0%) was longer than that of WHO grade III--IV patients (10 months; 3-year survival rate = 5.5%) (Log-rank *p* = 0.039) (Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}). The extent of resection (gross-total resection) was a protective factor, as was chemotherapy, in all glioma patients. Overall, gross-total resection was associated with a 33.3 (Log-rank *p* = 0.000, HR = 0.667, 95% CI = 0.545--0.817, *p* = 0.000) and 36.5% (Log-rank *p* = 0.000, HR = 0.63.5, 95% CI = 0.519--0.777, *p* = 0.000) decrease in OS and PFS mortality hazards, respectively. Median OS and PFS were 11 and 8 months, respectively, with 10.2% and 6.0% 3-year survival rates. In low-grade glioma patients, gross-total resection was associated with a 32.3% (Log-rank *p* = 0.000, HR = 0.677, 95% CI = 0.522--0.878, *p* = 0.003) and 35.8% (Log-rank *p* = 0.000, HR = 64.2, 95% CI = 0.496--0.831, *p* = 0.001) decrease in OS and PFS mortality hazards, respectively. Median OS and PFS were 11 and 8 months, respectively, with 12.5% and 7.1% 3-year survival rates. Finaly, in high-grade glioma patients, gross-total resection was associated with a 37.6% (Log-rank *p* = 0.002, HR = 0.62.4, 95% CI = 0.451--0.864, *p* = 0.004) and 39.3% (Log-rank *p* = 0.001, HR = 60.7, 95% CI = 0.439--0.840, *p* = 0.003) decrease in OS and PFS mortality hazard, respectively. Median OS and PFS were 10 and 8 months, respectively, with 6.9% and 4.5% 3-year survival rates. Treatment with chemotherapy was also associated with an overall reduced risk of death as measured by increased patient OS (3-year survival rate = 14.2%, median survival = 12 months, Log-rank *p* = 0.000, HR = 0.643, 95% CI = 0.528--0.782, *p* = 0.000) and PFS (3-years survival rate = 11.6%, median survival = 8 months, Log-rank *p* = 0.000, HR = 0.731, 95% CI = 0.602--0.889, *p* = 0.002). This same trend was observed in OS (3-year survival rate = 16.2%, median survival = 12 months, Log-rank *p* = 0.000, HR = 0.665, 95% CI = 0.517--0.855, *p* = 0.001) and PFS (3-year survival rate = 13.3%, median survival = 8 months, Log-rank *p* = 0.004, HR = 0.722, 95% CI = 0.523--0.926, *p* = 0.010) of low-grade glioma patients, and in OS (3-year survival rate = 11.3%, median survival = 12 months, Log-rank *p* = 0.001, HR = 0.617, 95% CI = 0.450--0.846, *p* = 0.003) of high-grade patients. No significant correlations were identified between patient gender and age, WHO tumor grade, or radiotherapy and prognosis as measured by OS and PFS.

###### Univariate analysis of the impact of clinical factors on glioma patient OS and PFS

  Variable              Classification   No. of patients/events   OS               No. of patients/events   PFS                                                                                       
  --------------------- ---------------- ------------------------ ----------- ---- ------------------------ ----------------------- ------- --------- ----------- ---- ------- ---------------------- -------
  Gender                Male             264/241                  30.3/7.0    11                            1                               262/248   17.6/4.9    8            1                      
                        Female           217/197                  31.8/8.2    10   0.583                    1.049 (0.869--1.267)    0.616   215/205   13.5/4.3    8    0.565   1.050 (0.872--1.263)   0.607
  Age (years)           \< 40            208/186                  33.2/9.1    12                            1                               205/191   17.1/6.1    8            1                      
                        ≥ 40             273/252                  29.3/6.3    11   0.202                    1.119/ (0.926--1.353)   0.244   272/262   14.7/3.5    8    0.135   1.136 (0.942--1.370)   0.182
  WHO grade             I--II            294/263                  33.0/9.0    12                            1                               292/275   17.1/5.4    8            1                      
                        III--IV          187/175                  27.8/5.5    10   0.039                    1.202 (0.993--1.456)    0.059   185/178   13.5/3.7    8    0.119   1.144 (0.947--1.381)   0.163
  Extent of resection   STR or NTR       153/150                  19.6/2.0    12                            1                               150/147   2.0/2.0     8            1                      
                        GTR              328/288                  36.3/10.2   11   0.000                    0.667 (0.545--0.817)    0.000   327/306   22.0/6.0    8    0.000   0.635 (0.519--0.777)   0.000
  Radiotherapy          No               44/37                    40.9/15.9   8                             1                               41/41     17.1/2.4    10           1                      
                        CRT              122/104                  21.3/12.9   9                             1.089 (0.747--1.589)    0.657   121/107   15.7/11.4   7            1.195 (0.830--1.720)   0.338
                        GK               315/297                  33.3/5.3    11   0.846                    1.096 (0.778--1.544)    0.599   315/305   15.6/2.6    8    0.543   1.108 (0.798--1.537)   0.54
  Chemotherapy          No               283/270                  24.7/0.0    9                             1                               282/282   14.9/0.0    7            1                      
                        Yes              198/168                  39.9/14.2   12   0.000                    0.643 (0.528--0.782)    0.000   195/171   16.9/11.6   8    0.000   0.731 (0.602--0.889)   0.002

OS: Overall survival; PFS: Progression free survival; WHO: World Health Organization; GTR: Gross-total resection; NTR: Near-total resection;

STR: Sub-total resection; CRT: Conformal radiation therapy; GK: Gamma knife; SR: Survival rate; MST: Median survival time(months).

HR: Hazard ratio; 95% CI: 95% Confidence interval.

Log-rank p values were calculated from Chi-Square test.

*p* values were calculated from Wald test.

*p* \< 0.05 indicates statistical significance.

###### Univariate analysis of the impact of clinical factors on low-grade glioma patient OS and PFS

  Variable              Classification   No. of patients/events   OS               No. of patients/events   PFS                                                                                      
  --------------------- ---------------- ------------------------ ----------- ---- ------------------------ ---------------------- ------- --------- ----------- ---- ------- ---------------------- -------
  Gender                Male             157/139                  35.0/9.8    12                            1                              156/143   21.8/7.9    8            1                      
                        Female           137/124                  30.7/8.4    12   0.241                    1.142 (0.895--1.456)   0.285   136/132   11.8/2.5    8    0.097   1.197 (0.944--1.518)   0.137
  Age (years)           \< 40            144/127                  33.3/10.4   12                            1                              142/131   17.6/6.7    8            1                      
                        ≥ 40             150/136                  32.7/7.7    11   0.487                    1.082 (0.849--1.378)   0.526   150/144   16.7/3.9    8    0.325   1.113 (0.878--1.411)   0.377
  WHO grade             I                35/30                    31.4/12.0   9                             1                              35/34     20.0/2.9    6            1                      
                        II               259/233                  33.2/8.7    12   0.792                    0.954 (0.652--1.396)   0.810   257/241   16.7/5.8    8    0.413   0.847 (0.610--1.252)   0.462
  Extent of resection   STR or NTR       97/95                    21.6/2.1    12                            1                              95/93     2.1/2.1     8            1                      
                        GTR              197/168                  38.6/12.5   11   0.001                    0.677 (0.522--0.878)   0.003   197/182   24.4/7.1    8    0.000   0.642 (0.496--0.831)   0.001
  Radiotherapy          No               24/19                    45.8/20.8   12                            1                              22/22     22.7/0.0    10           1                      
                        CRT              73/62                    20.5/13.2   12                            1.270 (0.758--2.128)   0.363   73/65     13.7/10.8   8            1.373 (0.843--2.237)   0.202
                        GK               197/182                  36.0/6.8    12   0.605                    1.196 (0.745--1.920)   0.459   197/188   17.8/3.8    8    0.299   1.176 (0.754--1.832)   0.474
  Chemotherapy          No               170/160                  28.2/0.0    10                            1                              170/170   16.5/0.0    8            1                      
                        Yes              124/103                  39.5/16.2   12   0.000                    0.665 (0.517--0.855)   0.001   122/105   18.0/13.3   8    0.004   0.722 (0.563--0.926)   0.010

OS: Overall survival; PFS: Progression free survival; WHO: World Health Organization; GTR: Gross-total resection; NTR: Near-total resection.

STR: Sub-total resection; CRT: Conformal radiation therapy; GK: Gamma knife; SR: Survival rate; MST: Median survival time (months).

HR: Hazard ratio; 95% CI: 95% Confidence interval.

Log-rank p values were calculated from Chi-Square test.

*p* values were calculated from Wald test.

*p* \< 0.05 indicates statistical significance.

###### Univariate analysis of the impact of clinical factors on high-grade glioma patient OS and PFS

  Variable              Classification   No. of patients/events   OS               No. of patients/events   PFS                                                                                 
  --------------------- ---------------- ------------------------ ----------- ---- ------------------------ -------------------- ------- --------- ----------- --- ------- -------------------- -------
  Gender                Male             107/102                  23.4/2.3    11                            1                            106/105   11.3/0.9    8           1                    
                        Female           80/73                    33.7/8.4    9    0.586                    0.926(0.684-1.254)   0.619   79/73     16.5/7.4    7   0.281   0.863(0.639-1.167)   0.340
  Age(years)            \< 40            64/59                    32.8/6.6    10                            1                            63/60     15.9/4.8    8           1                    
                        ≥ 40             123/116                  25.2/5.0    10   0.418                    1.126(0.822-1.541)   0.460   122/118   12.3/3.1    7   0.388   1.129(0.827-1.542)   0.445
  WHO grade             III              124/116                  29.8/5.1    11                            1                            123/118   13.8/4.1    8           1                    
                        IV               63/59                    23.8/6.3    9    0.471                    1.111(0.812-1.521)   0.510   62/60     12.9/3.2    7   0.443   1.114(0.816-1.521)   0.496
  Extent of resection   STR or NTR       56/55                    16.1/1.8    9                             1                            55/54     1.8/1.8     7           1                    
                        GTR              131/120                  32.8/6.9    10   0.002                    0.624(0.451-0.864)   0.004   130/124   18.5/4.5    8   0.001   0.607(0.439-0.840)   0.003
  Radiotherapy          No               20/18                    35.0/10.0   8                             1                            19/19     10.5/0.0    6           1                    
                        CRT              49/42                    22.4/12.6   9                             0.894(0.510-1.566)   0.695   48/42     18.8/12.5   7           1.005(0.579-1.744)   0.987
                        GK               118/115                  28.8/2.5    10   0.775                    1.008(0.612-1.660)   0.976   118/117   11.9/0.8    8   0.939   1.055(0.648-1.720)   0.829
  Chemotherapy          No               113/110                  19.5/1.8    9                             1                            112/112   12.5/3.6    7           1                    
                        Yes              74/65                    40.5/11.3   12   0.001                    0.617(0.450-0.846)   0.003   73/66     15.1/9.4    8   0.054   0.762(0.557-1.042)   0.088

OS: Overall survival; PFS: Progression free survival; WHO: World Health Organization; GTR: Gross-total resection; NTR: Near-total resection.

STR: Sub-total resection; CRT: Conformal radiation therapy; GK: Gamma knife; SR: Survival rate; MST: Median survival time (months).

HR: Hazard ratio; 95% CI: 95% Confidence interval.

Log-rank *p* values were calculated from Chi-Square test.

*p* values were calculated from Wald test.

*p* \< 0.05 indicates statistical significance.

According to Log-rank tests and Cox regression analysis, the two SNPs we studied were not correlated with OS or PFS in glioma patients (Table [5](#T5){ref-type="table"}). However, we found that the *IL-10* rs1800871 C/T genotype was associated with increased OS in low-grade glioma cases (3-year survival rate = 13.1%, median survival = 12 months, Log-rank *p* = 0.019, HR=0.745, 95% CI=0.573--0.969, *p* = 0.028), but not high-grade cases. We also found that the *PRKDC* rs7003908 C/C genotype correlated with poor prognosis in high-grade glioma patients as measured by OS (3-year survival rate = 0.0%, median survival = 6 months, Log-rank *p* = 0.000, HR = 4.556, 95% CI = 1.936--10.721, *p* = 0.001) and PFS (3-year survival rate = 0.0%, median survival = 4 months, Log-rank *p* = 0.000, HR = 4.430, 95% CI = 1.884--10.416, *p* = 0.001), although this was not observed in low-grade glioma patients.

###### Univariate analysis of the association between rs1800871, rs7003908 and glioma patient OS and PFS

  SNP-ID               Genotype   No. of patients/events   OS               No. of patients/events   PFS                                                                                      
  -------------------- ---------- ------------------------ ----------- ---- ------------------------ ----------------------- ------- --------- ---------- --- ------- ----------------------- -------
  low-grade I--II                                                                                                                                                                             
  rs1800871            C/C        36/35                    25.0/5.6    10                            1                               36/35     13.9/2.8   7           1                       
                       C/T        129/109                  39.5/13.1   12                            0.745 (0.573--0.969)    0.028   129/118   23.3/8.1   8           0.799 (0.619--1.033)    0.087
                       T/T        126/116                  28.6/5.3    11   0.019                    1.098 (0.752--1.603)    0.627   124/119   12.1/3.5   8   0.079   1.087 (0.745--1.585)    0.665
  rs7003908            A/A        188/168                  34.0/8.7    12                            1                               186/176   17.2/5.2   8           1                       
                       C/A        86/76                    32.6/11.4   12                            0.965 (0.736--1.265)    0.796   86/80     18.6/5.8   8           0.914 (0.701--1.190)    0.503
                       C/C        20/19                    25.0/0.0    12   0.843                    1.105 (0.687--1.777)    0.68    20/19     10.0/5.0   9   0.755   0.956 (0.595--1.536)    0.852
  high-grade III--IV                                                                                                                                                                          
  rs1800871            C/C        22/20                    31.8/9.1    11                            1                               22/20     18.2/9.1   8           1                       
                       C/T        93/88                    24.7/4.3    9                             1.133 (0.824--1.557)    0.444   91/89     13.2/2.2   7           1.105 (0.806--1.516)    0.536
                       T/T        71/67                    29.6/4.9    10   0.467                    0.883 (0.536--1.455)    0.626   71/68     11.3/4.2   8   0.598   0.908 (0.551--1.496)    0.704
  rs7003908            A/A        112/106                  32.1/3.1    10                            1                               110/107   13.6/2.7   8           1                       
                       C/A        69/63                    23.2/8.7    10                            0.935 (0.684--1.279)    0.676   69/65     14.5/5.8   8           0.979 (0.718--1.333)    0.891
                       C/C        6/6                      0.0/0.0     6    0.000                    4.556 (1.936--10.721)   0.001   6/6       0.0/0.0    4   0.000   4.430 (1.884--10.416)   0.001

SR: Survival rate; MST: Median survival time (months).

HR: Hazard ratio; 95% CI: 95% Confidence interval.

Log-rank *p* values were calculated using the Chi-Square test.

*p* values were calculated using the Wald test.

*p* \< 0.05 indicates statistical significance.

Multivariate analysis {#s2_3}
---------------------

Multivariate Cox regression analysis demonstrated that SNP genotype was an independent prognostic factor for OS and PFS after adjustment for the various clinical factors. In the present study, we identified correlations between rs1800871, rs7003908 and prognosis in different glioma grades (Table [6](#T6){ref-type="table"}). The *IL-10* rs1800871 C/T genotype correlated with better OS in low-grade glioma patients (adjusted HR = 0.736, 95% CI = 0.565--0.958, *p* = 0.022) and the *PRKDC* rs7003908 C/C genotype correlated with worse OS (adjusted HR = 4.288, 95% CI = 1.808--10.169, *p* = 0.001) and PFS (adjusted HR = 3.783, 95% CI = 1.601--8.943, *p* = 0.002) in high-grade glioma patients.

###### Multivariate analysis of the association between rs1800871, rs7003908 and glioma patient OS and PFS

  SNP-ID                Genotype   OS                      PFS                            
  --------------------- ---------- ----------------------- ------- ---------------------- -------
  low-grade I--II                                                                         
  rs1800871             C/C        1                               1                      
                        C/T        0.736 (0.565--0.958)    0.022   0.789 (0.610--1.020)   0.071
                        T/T        1.073 (0.735--1.567)    0.716   1.059 (0.726--1.545)   0.767
  rs7003908             A/A        1                               1                      
                        C/A        0.968 (0.738--1.270)    0.817   0.918 (0.705--1.196)   0.527
                        C/C        1.119 (0.696--1.799)    0.643   0.962 (0.599--1.547)   0.874
  high--grade III--IV                                                                     
  rs1800871             C/C        1                               1                      
                        C/T        1.149 (0.832--1.588)    0.399   1.169 (0.850--1.659)   0.336
                        T/T        0.879 (0.533--1.449)    0.612   0.929 (0.564--1.532)   0.774
  rs7003908             A/A        1                               1                      
                        C/A        1.038 (0.755--1.427)    0.82    1.033 (0.756--1.412)   0.839
                        C/C        4.288 (1.808--10.169)   0.001   3.783 (1.601--8.943)   0.002

OS: Overall survival; PFS: Progression free survival.

HR: Hazard ratio; 95% CI: 95% Confidence interval.

*p* values were calculated using the Wald test.

*p* \< 0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

Gliomas are the most common primary tumors of the central nervous system and several patient prognosis predictors have been identified, including patient age, WHO tumor grade, extent of tumor resection, and radiotherapy and chemotherapy regimen(s) \[[@R15]\]. Consistent with previous studies \[[@R16], [@R17]\], we found that chemotherapy and the extent of resection were key prognostic factors in glioma patients. Prognoses differed between low-grade and high-grade glioma patients. After WHO grade stratification, we found that rs1800871 in *IL-10* correlated with increased OS in low-grade glioma cases, while rs7003908 in *PRKDC* correlated with poor prognosis in high-grade cases.

Ours was the first study to associate the *IL-10* rs1800871 C/T genotype with improved survival in low-grade glioma patients. *IL-10* gene polymorphisms have been associated with multiple cancers, such as gastric \[[@R18]\], breast \[[@R19]\], and non-small cell lung cancer \[[@R20]\], as well as gliomas \[[@R9], [@R21]\]. Inflammation plays roles in all phases of tumor development, and IL-10, a well-known immuno-modulatory cytokine, may provide a functional link between inflammation and cancer \[[@R22]\]. Acuner-Ozbabacan, *et al.* \[[@R22]\] found that IL-10 deficiency allowed for pro-inflammatory cytokine induction and hindered anti-tumor immunity, thereby promoting tumor growth. Tanikawa, *et al.* \[[@R23]\] observed that high serum IL-10 levels enhanced the tumor-specific immune response and reduced tumor growth. These results were inconsistent with earlier findings by Kim, *et al.* \[[@R24]\], who proposed that IL-10 inhibition would promote the anti-tumor immune response. These contrary findings may be due to the intrinsically pleiotropic biological activity of IL-10 and the variability of cancer models \[[@R25]\], or possibly genetic factors between different races. The exact function of IL-10 in glioma is not clear; further studies are required to elucidate the mechanisms underlying the association between *IL-10* polymorphisms and glioma patient prognosis.

This study was also the first to demonstrate that the *PRKDC* rs7003908 C/C genotype was correlated with poor prognosis in high-grade glioma patients. Rs7003908 was previously associated with increased risk of glioblastoma multiforme \[[@R14]\], hepatocellular carcinoma \[[@R26]\], prostate cancer \[[@R27]\], and bladder cancer \[[@R28]\]. *PRKDC* encodes the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), which is critical in the DNA damage response (DDR) and maintenance of genomic stability \[[@R29]\]. Goodwin, *et al.* \[[@R30]\] suggested that DNA-PKcs suppression inhibited tumor metastasis. Their group observed that DNA-PKcs induced cell migration, invasion, and metastasis, and was highly activated in advanced tumors, independent of DNA damage indicators. The same group \[[@R29]\] showed that *PRKDC*, as a transcriptional regulator, might promote tumor initiation and progression. Additionally, *PRKDC* expression and activity is increased in numerous tumor types, such as colorectal cancer \[[@R31]\], esophageal cancer \[[@R10]\], and B-cell chronic lymphocytic leukemias \[[@R11]\]. In the present study, we observed reduced OS and PFS in high-grade glioma patients carrying the *PRKDC* rs7003908 C/C genotype. This mutation may be associated with increased *PRKDC* expression, activity, or receptor activation, any of which might promote cell proliferation.

In conclusion, our data indicated that chemotherapy and extent of tumor resection were associated with improved glioma patient prognosis. IL-10 SNP rs1800871 was associated with improved survival in low-grade glioma cases, while *PRKDC* SNP rs7003908 was correlated with poor prognosis in high-grade patients. Although the exact mechanisms remain unclear, our results suggest that these two SNPs may be useful biomarkers for predicting glioma patient outcomes. Additionally, IL-10 and DNA-PKcs may be promising therapeutic targets for treatment of advanced malignancies. Further functional studies are needed to evaluate associations between rs1800871 and rs7003908 polymorphisms and glioma patient prognosis.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

A total of 481 patients diagnosed with glioma at the Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Shaanxi Province (Xi\'an, China) between September 2010 and April 2016 were randomly enrolled in this study. We used the following detailed selection criteria: recently diagnosed and histologically confirmed to have glioma (glioma was diagnosed via imaging and pathological analysis); Han Chinese patient with no kinship; underwent regular follow-up; peripheral blood samples available; no previous history of other cancers; and no prior treatment for glioma or prior treatment with chemotherapy or radiotherapy. Histopathological diagnosis was confirmed according to the World Health Organization (WHO) classification in 2007.

Our study protocol adhered to the principles of the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of Tangdu Hospital. All patients gave written informed consent prior to participation in the study.

DNA extraction and genotyping {#s4_2}
-----------------------------

Genomic DNA was extracted from glioma patient peripheral blood samples (5 mL) using GoldMag-Mini Whole Blood Genomic DNA Purification Kits (GoldMag. Co. Ltd., Xi\'an, China) according to the manufacturer\'s protocols. DNA quantity was evaluated by spectrophotometry (DU530UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA). We designed polymerase chain reaction (PCR) and extension primers for the SNPs using the Sequenom MassARRAY Assay Design 3.0 software (Sequenom, San Diego, CA, USA). Sequenom MassARRAY RS1000 was utilized to genotype SNPs according to the manufacturer\'s protocol. We used Sequenom Typer 4.0 software for data management and analysis.

Clinical data and follow-up {#s4_3}
---------------------------

Patient treatment and survival (overall and progression-free) information was collected from a retrospective review of patient medical records or consultation with treating physicians. A standardized questionnaire was used to collect clinical data, including the date of diagnosis, follow-up date(s), patient age and gender, tumor histologic type, extent of resection, exact pathology, WHO grade, surgical methods, and postoperative radiotherapy and chemotherapy regimen(s). Follow-up consisted of outpatient visits, telephone interviews, and written communication with patients or their families. Clinical follow-up was performed in single-blind fashion with death as the end point. Glioma patients who were alive at the end of the follow-up period were excluded from the study. Data were stored electronically using the EpiData3.02 software, and validation, revision and conversion of assigned values were performed to establish the glioma patient database used for analysis.

Statistical analyses {#s4_4}
--------------------

SPSS 17.0 (SPSS, Chicago, IL, USA) was used to analyze follow-up and experimental data. Log-rank tests were used to compare survival curves. Univariate and multivariable Cox proportional hazard models were used to calculate crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs), respectively. Two-sided *p*-values \< 0.05 were considered statistically significant and were calculated using the Wald test. HRs were adjusted for other factors that could affect glioma outcome, such as patient age and gender, and extent of tumor resection.

It is our great honor to express heartfelt thanks to all of the patients, clinicians and other hospital staff who participated in and contributed to this study.
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